{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031886","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.969181+00:00","generated_at":"2026-05-31T09:17:13.950218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cocrystal Pharma posts Q2 net loss $5.3M, cash $18.1M; pipeline milestones set","bullets":["Q2 2024 net loss $5.3M ($0.54/sh) vs Q2 2023 net loss $4.2M ($0.41/sh); R&D spend $4.3M up 54% YoY.","Cash $18.1M at June 30 from $26.4M at Dec 31; runway expected to fund operations for next 12 months.","Topline results from Phase 2a influenza A human challenge study (oral CC-42344) expected in 2025.","In vitro data shows CC-42344 inhibits avian influenza A (H5N1) PB2 protein recently found in U.S. dairy cows.","Topline Phase 1 results for pan-coronavirus/norovirus oral CDI-988 expected late 2024 / early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031886","json":"https://secwatch.observer/filing/0001493152-24-031886.json","markdown":"https://secwatch.observer/filing/0001493152-24-031886.md","text":"https://secwatch.observer/filing/0001493152-24-031886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224031886/0001493152-24-031886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224031886/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:17:13.950218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}